PensionDanmark Pensionsforsikringsaktieselskab 13F: Cuts LLY Stake by $4.1M
Key Points
- PensionDanmark trimmed its Eli Lilly and Company (NYSE:LLY) position by 3,570 shares, ending the period with 145,819 shares valued at about $168.7 million.
- Eli Lilly trades near $1,240.56, sitting comfortably above its 50-day moving average of $1,179.04 and its 200-day average of $1,079.02.
- Analyst coverage remains generally positive with a consensus buy rating and a mean price target of $1,328.05 ahead of the October 29 earnings release.
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
PensionDanmark trimmed its stake in Eli Lilly and Company (NYSE:LLY) during the period, cutting its holdings by 3,570 shares to end with 145,819 shares. The disclosure came in a Form 13F filed with the Securities and Exchange Commission on October 19, 2026. The remaining position was valued at roughly $168.7 million based on the filing's figures. The adjustment reflects a 2.4% reduction from the previous count of 149,389 shares.
LLY
Eli Lilly and Company
PensionDanmark Pensionsforsikringsaktieselskab vs. the S&P 500
Hypothetical returns from PensionDanmark Pensionsforsikringsaktieselskab's disclosed trades, not real profit or advice. How we model this.
What Changed in PensionDanmark's Eli Lilly and Company Position
PensionDanmark adjusted its exposure to the major drugmaker by shedding 3,570 shares over the quarter. The fund previously held 149,389 shares of the healthcare giant. Following the 2.4% decrease, the investor's stake stands at 145,819 shares worth about $168.7 million.
Other Institutional Activity in Eli Lilly and Company
Other large institutional investors also made adjustments to their Eli Lilly holdings around the same time. Lilly Endowment, Inc reduced its holdings by 1,516,238 shares, or 1.7%, ending with 90,376,798 shares worth about $112.1 billion. PNC Financial Services Group, Inc. trimmed its position by 5,133 shares, or 0.0%, closing the period with 51,322,720 shares valued at about $63.7 billion.
Eli Lilly and Company Stock Down 1.3%
Eli Lilly shares recently traded around $1,240.56 as of October 20, 2026, down about 0.9% from the closing price of $1,252.06 on the October 19 filing date. The stock sits about 4.0% below its 52-week high of $1,292.65 and 58.3% above its 52-week low of $783.85. The share price is currently 5.2% above its 50-day moving average of $1,179.04 and 15.0% above its 200-day moving average of $1,079.02. The company commands a market capitalization above $1.11 trillion and has a trailing P/E ratio of 42.0.
Recent Earnings
Eli Lilly posted trailing twelve-month revenue of $79.7 billion alongside earnings of $29.79 per share. The firm generated a return on equity of 102.3% and a net profit margin of 33.5%, accompanied by year-over-year revenue growth of 47.7%. The company is scheduled to report its next financial results on October 29, 2026.
Dividend
The drug manufacturer maintains an annual dividend yield of 0.55% with a payout ratio of 21.7%.
Insider Buying and Selling at Eli Lilly and Company
Company insiders executed several transactions in recent months. On June 10, 2026, officer Ilya Yuffa sold 2,500 shares at an average price of $1,150.77 for a total of $2,876,925. General Counsel Anat Hakim sold 5,000 shares on August 7, 2026, at $1,190.00 each, totaling $5,950,000. On August 10, 2026, officer Donald A Zakrowski disposed of 2,000 shares at $1,185.01 per share for a value of $2,370,020. Finally, officer Patrik Jonsson sold 6,500 shares on August 17, 2026, at $1,175.10 per share, realizing $7,638,150.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock ahead of the filing. On September 22, 2026, TD Cowen reiterated its buy rating with a $1,250.00 price target. JP Morgan maintained its overweight rating on September 28, 2026, raising its target from $1,400.00 to $1,500.00. Morgan Stanley maintained an overweight rating on October 7, 2026, lifting its target to $1,430.00 from $1,419.00. Cantor Fitzgerald maintained an overweight rating on October 8, 2026, raising its target to $1,440.00 from $1,410.00. RBC Capital reiterated its outperform rating on October 12, 2026, keeping its target at $1,500.00. The stock holds a consensus buy recommendation from 30 analysts, with a mean price target of $1,328.05.
About Eli Lilly and Company
Eli Lilly and Company is a major healthcare enterprise headquartered in Indianapolis, Indiana. The firm discovers, develops, manufactures, and distributes pharmaceutical treatments globally, focusing on areas such as diabetes, oncology, and immunology. Its therapies are distributed across the United States, Europe, Asia, and other international markets.
Bottom Line
Investors will look toward Eli Lilly's upcoming earnings report on October 29, 2026, for fresh updates on product demand and financial performance. The stock continues to trade near the upper end of its 52-week range as institutional holders adjust their portfolios.
Related Filing Alerts
Source: PensionDanmark Pensionsforsikringsaktieselskab's 13F filing on $LLY (Oct 19, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts